5asd -...

COLLABORATION

PARTNERSHIPS

QUOTES FROM A RECENT

TRANSACTION PARTNER

SCIENCE

SP

EE

D

AC

CE

SS

IBLE

CUTTING EDGE

PR

OV

EN

TR

AC

K R

EC

OR

D

“We had a number of attractive strategic options in front of us, however Bristol-Myers Squibb and its focus on exploring our biology won the day.”

“Bristol-Myers Squibb was the right partner who brought the optimal deal structure, considerable capabilities and a commitment of resources.”

Anna Rivkin Global Lead, Fibrotic Diseases anna.rivkin@bms.com

Mohamed Ragab Head, Immuno-Oncology/Oncology mohamed.h.ragab@bms.com

Timothy Fisher Global Lead, Immuno-Oncology/Oncology timothy.fisher@bms.com

Saryah Azmat Manager, Immuno-Oncology/Oncology saryah.azmat@bms.com

Fang Zhang Manager, Immuno-Oncology/Oncology fang.zhang@bms.com

TECHNOLOGY TRANSACTIONS

Donnie McGrath Vice President, Search and Evaluation

Steve Yoder Head, Specialty stephen.yoder@bms.com

Martin Crook Global Lead, Cardiovascular martin.crook@bms.com

Mireia Gomez-Angelats Global Lead, Genetically Defined Diseases mireia.gomezangelats@bms.com

Stephen O’Keefe Global Lead, Immunoscience stephen.o’keefe@bms.com

SEARCH AND EVALUATION

Graham Brazier Vice President, Transactions

Matt Bunn Genomics, Bioinformatics and Clinical Imaging matt.bunn@bms.com

Michael Cucolo Drug Delivery and Formulation Sciences michael.cucolo@bms.com

Andrea Lauber Clinical Biomarkers and Pharmacodiagnostics andrea.lauber@bms.com

Karen Martell Biologics Discovery Platforms karen.martell@bms.com

Rob Penhallow Chemistry and ADME/Toxicology robert.penhallow@bms.com

Ping Cao Lead Discovery and Optimization and Protein Sciences and Structure ping.cao1@bms.com

BUSINESS DEVELOPMENT CONTACTS

- Paul Biondi, Senior Vice President & Head of Business Development ”“We have a distinct, decisive approach to partnering that leverages our best with the best of our partners to speed transformational medicines to patients.

Combining passion, science and experience to deliver innovation together

PARTNERING TO SPEED TRANSFORMATIONAL

MEDICINES TO PATIENTS

5asdFor more information please visit: www.bms.com/partnering

5asd

TECHNOLOGY INTERESTS

“”

External innovation and collaboration has been a critical component to building our differentiated portfolio of specialty medicines and a hallmark of our success.- Giovanni Caforio, M.D. Chief Executive Officer

DRUG PLATFORMS AND NOVEL TECHNOLOGIES

• Access to new chemical matter, including macrocycle and fragment libraries

• Novel antibody drug conjugate (ADC) technology

• Subcutaneous controlled release

• Oral delivery of millamolecules and macrocyclic peptides

• ADME/Toxicology: Modeling and prediction technology

• High throughput, label free screening and protein expression platform

• Emerging structure determination platform

• Non-invasive diagnostics and translational biomarkers

• Improved methods for single cell capture, and genomic characterization

• Scalable bioinformatics analysis capabilities using principles for reproducible research

OUR STRATEGIC FOCUS - 2016

Immuno-Oncology

• Focus on approaches that are direct acting on the immune system

- Novel immune checkpoint inhibitors and co-stimulatory agents

• Tumor intrinsic targets with demonstrated impact on anti-tumor immunity

• Tumor microenvironment

Oncology • Agents displaying synergy with immune

checkpoint inhibitors

• Established non-immunosuppressive mechanisms of action

• New approaches to validated cancer pathways

• Emerging areas of cancer biology

• Antibody drug conjugates (ADC) – novel targets and late preclinical/clinical-stage programs in areas of unmet medical need

Out of Scope: Supportive care – Bristol-Myers Squibb focuses on therapeutics

Immunoscience • Assets with transformative potential in inflamma-

tory arthritis, SLE/lupus nephritis, IBD and other immune-mediated diseases with high unmet needs

Out of Scope: allergy and asthma

Cardiovascular • Heart failure: acute, post-acute, HFrEF,

HFpEF, cardiomyopathy

• Highly validated targets addressing CV risk with clear specialty medicine development paths

Out of Scope: LDL lowering, HDL raising, anticoagulant, hypertension

Fibrosis • Mechanisms which selectively block fibroblast

and stellate cell activation, or enhance productive healing through pro-resolution macrophages

• Modulation of TGF-β pathway in a tissue or cell specific manner. Selectively modulate myofibroblast activity via the TGF-β pathway

• Target regenerative mechanisms with potential for fibrosis reversal and repair

• Mechanisms which promote extracellular matrix turnover or epithelial cell protection

• Non-invasive diagnostics and biomarkers which correlate with disease pathology, or facilitate identification of patients who are likely to progresses rapidly, or enable identification of patients likely to respond to therapies

• Priority fibrotic diseases include: NASH fibrosis; NASH cirrhosis, Idiopathic Pulmonary Fibrosis (IPF); Fibrotic Interstitial Lung diseases

Genetically Defined Diseases (GDD)

• Focus on monogenic diseases

• Clinical-stage opportunities in rare/orphan diseases targeting at or near mutant protein

• Special interest in clinical and preclinical opportunities targeting Duchenne Muscular Dystrophy, synuclein, Nav1.7, and familial cardiomyopathy (fCM – hypertrophic or dilated)

BRISTOL-MYERS SQUIBB DEVELOPMENT PORTFOLIO BY DISEASE AREA

Data as of May 1, 2016

1 Approved in at least one major market (US, EU, JP)

2 In Phase III development or currently under regulatory review

Marketed 1

Phase III 2

Phase II

Phase I

▶ ACTIVE PARTNERSHIP

SOURCED INNOVATION

Genetically Defined Diseases

Anti-Myostatin

Anti-eTau

Oncology

SPRYCEL

BET Inhibitor

Ulocuplumab (Anti-CXCR4)

Anti-Fucosyl GM1

Anti-HER2

Mesothelin ADC

Fibrotic Diseases

PEG-FGF21 (1)

Galectin-3 Inhibitor

LPA1 Antagonist

Pentraxin-2

PEG-FGF21(2)

Immuno-Oncology

YERVOY

OPDIVO

EMPLICITI

PROSTVAC

Urelumab (Anti-CD137)

Lirilumab (Anti-KIR)

Anti-LAG3

▶▶

Anti-GITR

Anti-CSF 1R

▶▶

▶▶

IDO Inhibitor

Immunoscience

ORENCIA

NULOJIX

Lulizumab (Anti-CD28)

BTK Inhibitor

Anti-CD40L

Anti-CD40

TYK2 Inhibitor

▶

Anti-PD-L1

Cardiovascular

ELIQUIS

IKur Inhibitor

Factor XIa Inhibitor

PAR4 Antagonist

Nitroxyl Donor

▶

Global product names appearing in italics represent the BMS-owned registered U.S. trademark for that product; however, PROSTVAC is a trademark of BN ImmunoTherapeutics Inc.

Gene TherapyRNA Oligonucleotides

Small Molecules Biologics

Antibody Drug Conjugates Millamolecules

Drug Delivery Technology